Liraglutide improves peripheral perfusion and markers of angiogenesis and inflammation in people with type 2 diabetes and peripheral artery disease: An 18‐month follow‐up of a randomized clinical trial
In people with type 2 diabetes and PAD, liraglutide increased peripheral perfusion, with amelioration of markers of angiogenesis and inflammation over an 18-month follow-up.
Authors
- Miriam Longo (ORCID: https://orcid.org/0000-0002-6459-5854)
- Mariluce Barrasso
- Antonietta Maio (ORCID: https://orcid.org/0009-0000-7720-8078)
- Giuseppe Bellastella (ORCID: https://orcid.org/0000-0002-4748-321X)
- Maurizio Gicchino (ORCID: https://orcid.org/0000-0002-2976-7948)
- Lorenzo Scappaticcio (ORCID: https://orcid.org/0000-0003-2972-9551)
- Maria Ida Maiorino (ORCID: https://orcid.org/0000-0003-4659-7546)
- Katherine Esposito (ORCID: https://orcid.org/0000-0002-3652-5154)
- Paola Caruso (ORCID: https://orcid.org/0000-0002-4756-2022)
- Dario Giugliano (ORCID: https://orcid.org/0000-0002-9377-873X)
- Mariangela Caputo
- Nicole Di Martino
- Carla Carbone
Institutions
- University of Campania "Luigi Vanvitelli" (IT)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-04-25
- DOI
- https://doi.org/10.1111/dom.16419
- Citations
- 8
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 10.36